This inventor holds 1 USPTO granted patent. Top assignee: Japanese Foundation for Cancer Research. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Tetsuo Mashima: Innovator in Cancer Research
Introduction
Tetsuo Mashima is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer research, particularly in the development of biomarkers for predicting therapeutic effects.
Latest Patents
Tetsuo Mashima holds a patent for "Biomarkers, test method, and test kit for predicting therapeutic effect of anti-VEGFR-2 antibody drug." This patent focuses on predicting the therapeutic effect and prognosis after administering an anti-VEGFR-2 antibody drug, specifically ramucirumab. The prediction is achieved by measuring various biomarkers, including VEGF-A, VEGF-D, sVEGFR-2, SDF-1α, and cNRP1. This innovation provides a valuable tool for assessing the effectiveness of the anti-VEGFR-2 antibody drug.
Career Highlights
Tetsuo Mashima is affiliated with the Japanese Foundation for Cancer Research, where he continues to advance his research and innovations. His work has the potential to significantly impact cancer treatment and patient outcomes.
Collaborations
Tetsuo collaborates with notable colleagues, including Takeru Wakatsuki and Hiroyuki Seimiya, who contribute to his research efforts and innovations in the field.
Conclusion
Tetsuo Mashima's contributions to cancer research through his innovative patent highlight his role as a key figure in the scientific community. His work continues to pave the way for advancements in cancer treatment and patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile